 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
2008 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of Cranberry Juice on Population Pharmacokinetics of Amoxicillin and Cefaclor | 3/14/2008 10:08:19 PM | Oral Presentation: Applications | |
Julie Antic (1,2), Céline M. Laffont (1), Didier Concordet (2). | Some Stochastic Algorithms For The Smooth Non Parametric (SNP) Estimator | 3/28/2008 9:53:06 AM | Poster: Methodology- Algorithms |
Use of mechanistic models to estimate target antigen load for monoclonal antibodies | 3/31/2008 9:03:47 PM | Poster: Applications- Biologicals/vaccines | |
M.A.Barras(1,2), S.B.Duffull(3), J.J.Atherton(4), B Green(1) | Individualized compared with conventional dosing of enoxaparin. | 3/15/2008 1:28:01 PM | Oral Presentation: Applications |
Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records | 3/16/2008 2:34:20 PM | Oral Presentation: Applications | |
Covariate Model Building Method for Nonparametric Estimation Method in NONMEM VI: Application to Simulated Data | 3/31/2008 7:55:38 PM | Poster: Methodology- Other topics | |
Population pharmacokinetics of AZT and its active metabolite AZT-TP in HIV patients: joint modelling and design optimisation | 3/31/2008 3:12:07 PM | Poster: Applications- Anti-infectives | |
C. Becker(1), K. Coboeken(1), L. Kuepfer(1), J. Lippert(1), R. Nubbemeyer(2), H. Blode(2) | Whole-Body Physiologically-based Pharmacokinetic (WB-PBPK) Population Modelling to Simulate the Influence of Weight and Age on the Pharmacokinetics (PK) of a combined Oral Contraceptive Containing Drospirenone (DRSP) and Ethinylestradiol (EE) | 3/31/2008 5:52:04 PM | Poster: Applications- Other topics |
Clinical Trial Simulation to Estimate the Sample Size for Investigation of the Impact of a Drug A on the Pharmacokinetics of Methotrexate, a common co-medication used in Rheumatoid Arthritis (RA) | 4/1/2008 1:20:45 PM | Poster: Methodology- Other topics | |
Using VT (total volume of distribution from PET) in estimating the PK-Receptor Occupancy relationship in the absence of reference regions. | 3/31/2008 8:54:10 PM | Poster: Applications- CNS | |
Martin Bergstrand (1), Erik Söderlind (2), Mats O Karlsson (1) | Modeling of gastro-intestinal tablet transit and its’ effect on drug release and absorption for felodipine extended release tablet under fed or fasting conditions | 3/17/2008 10:49:12 AM | Oral Presentation: Lewis Sheiner Student Session |
Properties of different tests to detect the effect of a genetic covariate on pharmacokinetic parameters using the SAEM algorithm for several designs | 3/29/2008 8:12:41 PM | Poster: Methodology- Algorithms | |
A comparison of a genetic algorithm based automated search algorithm to standard stepwise approach for population pharmacokinetics using NONMEM. | 3/31/2008 12:40:16 AM | Poster: Methodology- Model evaluation | |
A Bayesian Meta-Analysis of Longitudinal Data in Placebo Controlled Studies with Naproxen | 3/31/2008 11:22:57 AM | Poster: Methodology- Other topics | |
Modeling and simulation to assess the use of change in tumor size as primary endpoint in Phase II studies in oncology | 3/31/2008 5:56:40 PM | Poster: Applications- Oncology | |
Massimo Cella(1), Meindert Danhof(1), Oscar Della Pasqua(1,2) | Randomisation to exposure in early paediatric trials: an analysis on the influence of the dose on the heterogeneity in the response to abacavir. | 3/27/2008 4:29:14 PM | Poster: Methodology- Design |
Pascal Chanu (1), Bruno Reigner (1), Nathalie Schultze (1), Ronald Gieschke (1), Nicolas Frey (1) | Decisive support of Modeling & Simulation for getting drug approval in the context of safety concern on the drug class | 3/30/2008 9:48:39 AM | Poster: Applications- Other topics |
Population PK/PD modelling of functional receptor occupancy in a first-time-in human study | 3/31/2008 5:43:30 PM | Poster: Applications- Other topics | |
Population modeling of the relationship between ropinirole systemic exposure and efficacy in Parkinson’s disease | 3/31/2008 10:38:37 PM | Poster: Applications- CNS | |
How to show average bioequivalence of concentrations in a test sample with a reference population pharmacokinetic model? | 3/29/2008 4:33:46 PM | Poster: Methodology- Other topics | |
Marylore Chenel(1), Laetitia Canini(1), Kayode Ogungbenro(2) and Emmanuelle Foos-Gilbert(1) | Optimal design of QTc interval measurements for circadian rhythm determination | 3/29/2008 4:26:08 PM | Poster: Methodology- Design |
Phoenix platform, WinNonlin, Trial Simulator, WinNonlin AutoPilot, and PKS (a PK/PD data repository) | 5/15/2008 7:21:19 AM | Software demonstration | |
L. Claret(1), F. Schaedeli Stark(2), F. Sirzen(2), R. Gieschke(2), R. Bruno(1) | A modeling framework to simulate Xeloda dose intensity and survival in colorectal cancer | 3/28/2008 3:36:02 PM | Oral Presentation: Applications |
Population pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus | 3/31/2008 5:14:18 PM | Poster: Applications- Anti-infectives | |
Modelling is seldom used to describe pharmacokinetics in phase I clinical trials | 3/27/2008 10:52:43 AM | Poster: Applications- Other topics | |
Cian Costello (1), Stefaan Rossenu (2), An Vermeulen (2), Adriaan Cleton (2), Adrian Dunne (1) | A Time Scaling Approach to Develop an In Vitro-In Vivo Correlation (IVIVC) Model Using a Convolution-Based Technique | 3/26/2008 1:22:12 PM | Poster: Methodology- Other topics |
Implementing Receptor Theory in PK-PD Modeling | 5/14/2008 8:28:47 AM | Tutorial | |
Modeling and Simulation to Integrate Efficacy and Safety Data Following Full Development: a Case Study in Schizophrenia and Bipolar Disorder | 3/20/2008 11:28:19 AM | Poster: Applications- CNS | |
Optimal window design of blood pressure time measurements in hypertensive dippers and non-dippers using ABPM: Application of the compound D-optimality approach. | 3/29/2008 12:39:12 PM | Poster: Methodology- Design | |
Evaluating the Influence of Different Sources of Variability in the PK/PD Tumor Growth Inhibition (TGI) Model | 5/15/2008 4:20:31 PM | Poster: Applications- Oncology | |
Assessment of pharmacokinetic variability of fondaparinux in 809 patients treated after major orthopedic surgery: the POP-A-RIX study | 3/27/2008 11:25:22 AM | Poster: Applications- Coagulation | |
Paolo Denti (1), Alessandra Bertoldo (1), Paolo Vicini (2) and Claudio Cobelli (1) | Comparison of Different Population Analysis Approaches to the IVGTT Glucose Minimal Model | 4/1/2008 12:05:35 AM | Poster: Applications- Endocrine |
Automatic Selection of Optimal Configuration of Artificial Neural Networks | 3/31/2008 4:09:12 PM | Poster: Methodology- Algorithms | |
Population analysis of plasma and intracellular pharmacokinetics of indinavir in HIV-1 infected patients with a stable antiretroviral therapy | 3/28/2008 5:56:22 PM | Poster: Applications- Anti-infectives | |
PP Tanos(1), SB Duffull(1,2), CMJ Kirkpatrick(1), DG Lalloo(3), GK Isbister (4) | A system model for the clotting cascade challenges clinical management of snake bites. | 3/20/2008 2:06:12 AM | Oral Presentation: Applications |
Simplified programming of population model user interfaces | 2/20/2008 4:56:05 PM | Poster: Applications- Other topics | |
S. Fanta(1), S. Jönsson(2), M.O. Karlsson(3), C. Holmberg(4), K. Hoppu(1), J.T. Backman(1) | Population Pharmacokinetics of Cyclosporine in Paediatric Renal Transplant Recipients | 3/31/2008 1:19:22 PM | Poster: Applications- Other topics |
Hands-On Demonstration of PDx-Pop® v3.0; Tools for Expediting Population Analysis | 5/7/2008 4:53:29 PM | Software demonstration | |
Simulations of bioequivalence trials using physiological-pharmacokinetic in single dose and steady state scenarios. Which scenarios are refusable? | 4/1/2008 12:18:53 PM | Poster: Methodology- Model evaluation | |
G. Ferron (a), L. Klumpers (b), Joop van Gerven(b), and C. Roy (a) | PK and PK/PD modeling of CB1 blocker antagonism of THC induced CNS and Heart Rate effect | 3/3/2008 8:53:20 PM | Poster: Applications- CNS |
N. Frances (1), L. Claret (2), F. Schaedeli Stark (3), R. Bruno (2), A. Iliadis (1) | Modeling of longitudinal tumor size data in clinical oncology studies of drugs in combination | 3/31/2008 11:40:25 AM | Poster: Applications- Oncology |
Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns | 3/5/2008 5:23:33 PM | Poster: Applications- Anti-infectives | |
Lena E. Friberg* (1), Rik de Greef (2), Thomas Kerbusch (2), Mats O. Karlsson (1) | Modeling and Simulation of the Asenapine Exposure-Response and Drop-Out in Acute Schizophrenia | 3/25/2008 10:49:28 AM | Oral Presentation: Applications |
Lena E. Friberg* (1), Marie Sandström (1,2), Mats O. Karlsson (1) | Scaling the Time-Course of Myelosuppression from Rats to Patients with a Semi-Physiological Model | 4/1/2008 7:20:14 AM | Poster: Applications- Oncology |
García MJ, Santos Buelga D, Cabrera S, Fernandez de Gatta MM, Domínguez-Gil | Population Pharmacokinetics of Efavirenz in HIV-infected patients: Pharmacogenetic analysis | 5/28/2008 9:35:43 PM | Poster: Applications- Anti-infectives |
Simultaneous population pharmacodynamic modelling of the growth hormone and insulin-like growth factor-I effects after deep subcutaneous administration of Lanreotide Autogel® in acromegalic patients. Application of Nonparametric estimation method in NONMEM | 3/31/2008 2:30:26 PM | Poster: Applications- Endocrine | |
Biopharmaceutic and pharmacodynamic characterization of the in vitro anti-proliferative effect of new delivery systems of Cisplatin | 3/31/2008 2:27:26 PM | Poster: Applications- Oncology | |
A Differential Equations Approach to In Vitro – In Vivo Correlation Modelling in NONMEM | 3/19/2008 1:05:06 PM | Poster: Methodology- Algorithms | |
Nonparametric Modeling and Population Approach to the Individualized Heart Rate Correction of the QT Interval | 3/31/2008 1:45:28 PM | Poster: Applications- CVS | |
Pharmacokinetics of oral single-dose clomiphene citrate (CC) in polycystic ovary patient with anovulatory infertility | 4/14/2008 1:24:13 PM | Poster: Applications- Endocrine | |
Indirect Response Models with Positive Feedback: Equations, Properties, and Possible Applications | 3/29/2008 6:56:16 PM | Poster: Methodology- Other topics | |
Parameter Estimates of Population Models: Comparison of Nonmem Versions and Estimation Methods | 3/19/2008 6:02:46 PM | Poster: Methodology- Algorithms | |
Application of Identifiability Analysis Algorithm to Population PK of the Drug with Target-Mediated Drug Disposition | 3/19/2008 6:12:06 PM | Poster: Methodology- Algorithms | |
Leonid Gibiansky (1), Ekaterina Gibiansky (2),Tarundeep Kakkar (3), Peiming Ma(3) | Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters | 3/19/2008 6:08:29 PM | Poster: Methodology- Algorithms |
Ihab G. Girgis, Jeremy Hing, Partha Nandy, Filip De Ridder, and Surya Mohanty | Bayesian Modeling of QT Interval: Focus on Baseline Measurements | 3/11/2008 2:53:41 PM | Poster: Applications- CVS |
Analysing Raw Count data from an In Vitro Target Occupancy Assay to Select Doses for Human Safety/Tolerability Trial | 3/31/2008 8:31:57 PM | Poster: Applications- CNS | |
How Disease Models can reduce late phase attrition rate to half by 2015 | 5/23/2008 1:02:09 PM | Oral Presentation: Applications | |
A Population Pharmacokinetic Study of Plasma and Intrapulmonary Concentrations of Rifampin | 3/28/2008 12:02:08 AM | Poster: Applications- Anti-infectives | |
Influence of Rifampin Pharmacokinetic Variability on Antibacterial Effect and Prevention of Resistance in Pulmonary Tuberculosis: a Simulation Study | 3/28/2008 12:13:26 AM | Poster: Applications- Anti-infectives | |
Alternative parameterisations of saturable (Emax) models allowing for nesting of non-saturable models | 3/31/2008 2:59:35 PM | Poster: Methodology- Other topics | |
Alteration of glucose and insulin regulatory networks for the treatment of type 2 diabetes mellitus | 3/31/2008 4:04:48 PM | Poster: Applications- Endocrine | |
Informative Study Designs to Identify True Parameter-Covariate Relationships | 3/12/2008 12:59:02 AM | Poster: Methodology- Design | |
Accelerating the Rate of Adoption of New Pharmacometrics Platforms Using Formal Tools For Model Interconversion | 3/31/2008 10:58:28 PM | Poster: Methodology- Algorithms | |
Open Statistical Services | 6/24/2008 5:38:23 PM | Software demonstration | |
Emma K. Hansson(1), Johan Wallin(1), Marie Sandström(1,2), Mats O. Karlsson(1), Lena E. Friberg(1) | Comparison of Inter-Occasion and Inter-Individual Variability in Chemotherapy- Induced Myelosuppression | 3/28/2008 9:05:11 PM | Poster: Applications- Oncology |
The Shape of the Myelosuppression Time-course is Related to the Probability of Developing Neutropenic Fever in Patients with Docetaxel-induced Grade IV Neutropenia | 3/28/2008 11:24:04 AM | Poster: Applications- Oncology | |
Patient compliance estimated from pharmacokinetic sample: application to Imatinib | 3/31/2008 2:03:26 PM | Poster: Methodology- Other topics | |
Simulation and Design Considerations for Noninferiority Trials in Phase II | 3/31/2008 10:19:12 PM | Poster: Methodology- Design | |
Stuck in Modelling – Attempts to describe disease progress and the action of oral hypoglycaemic agents in type 2 diabetes | 3/31/2008 11:07:52 PM | Oral Presentation: Stuck in Modelling | |
Delayed response to hypoglycaemic agents and effect on progression of type 2 diabetes | 3/31/2008 11:11:45 PM | Poster: Applications- Endocrine | |
Parameter estimation in non-linear mixed effects models using interval analysis | 3/31/2008 2:58:16 PM | Oral Presentation: Stuart Beal Methodology Session | |
Andrew C. Hooker, Pontus Pihlgren, Kajsa Harling, E. Niclas Jonsson and Mats O. Karlsson | Xpose and Perl Speaks NONMEM (PsN) | 5/19/2008 7:27:27 PM | Software demonstration |
Joakim Nyberg, Stefanie Henning, Mats O. Karlsson and Andrew C. Hooker | PopED | 5/19/2008 7:26:26 PM | Software demonstration |
Four Programs for Writing and Running Nonmem Scripts. | 4/1/2008 4:41:20 AM | Software demonstration | |
C. Hoyo-Vadillo(1), H. González(2), E. Romero(2) and J. Pérez Urízar(3) | Pharmacokinetics model for Nifedipine administered to Healthy Volunteers. | 3/31/2008 7:21:54 AM | Poster: Applications- CVS |
Application of modelling and simulation in clinical oncology | 4/18/2008 8:41:27 AM | Oral Presentation: Applications | |
Matthew M Hutmacher (1), Roberta Bursi (2), Sunny Chapel (1), Thomas Kerbusch (2) | Implications for animal-human scaling of the parallel elimination profile PK model | 3/31/2008 3:47:09 PM | Poster: Methodology- Other topics |
A Population PK model to evaluate variability in oral absorption using gamma scintigraphy | 3/28/2008 5:38:50 PM | Poster: Methodology- Model evaluation | |
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling | 3/28/2008 12:14:01 PM | Poster: Methodology- Other topics | |
Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of oral drug absorption, tissue distribution, metabolism and elimination in healthy and disease populations using in vitro knowledge | 5/6/2008 2:53:19 PM | Software demonstration | |
Identification of the Mechanism of Action of a Glucokinase Activator from OGTT Data in Type 2 Diabetics Using an Integrated Glucose-Insulin Model | 3/31/2008 8:53:17 PM | Poster: Applications- Endocrine | |
R Jelliffe, A Schumitzky, D Bayard, R Leary, M Van Guilder, M Neely, S Goutelle, and A Bustad. | The USC*PACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens. | 3/12/2008 12:30:37 AM | Software demonstration |
The pharmacokinetics of the once-daily human glucagon-like peptide-1 analogue, liraglutide, across 5 trials in healthy subjects and type 2 diabetics after single and multiple dosing | 4/2/2008 12:48:18 PM | Poster: Applications- Other topics | |
A Tutorial on Visual Predictive Checks | 5/19/2008 7:30:42 PM | Tutorial | |
Population PK-PD modeling of E7820 and α2-integrin expression on platelets in patients with solid tumors and lymphomas | 3/7/2008 2:40:18 PM | Poster: Applications- Oncology | |
A simple infrastructure and graphical user interface (GUI) for distributed NONMEM analysis on standard network environments | 1/29/2008 4:25:12 PM | Poster: Methodology- Other topics | |
The Effect of Study Design on Pharmacokinetics in Patients with Impaired Renal Function | 3/31/2008 11:40:11 AM | Poster: Methodology- Design | |
Deconvolution of Insulin Secretion Rates | 3/14/2008 11:02:46 AM | Oral Presentation: Applications | |
Linear Mixed Effects models based on Stochastic Differential Equations in R | 3/14/2008 11:04:18 AM | Poster: Methodology- Algorithms | |
C. Kloft (1), W. Huisinga (2), H.G. Schaefer (3), P. Noertersheuser (3) | Launch of the Graduate Research Training (GRT) Program 'Pharmacometrics & Computational Disease Modelling' in Germany | 3/31/2008 6:16:31 PM | Poster: Methodology- Other topics |
Predictive Value of Allometric Scaling for Estimation of Propofol Clearance in Neonates, Infants and Adolescents | 3/21/2008 3:56:52 PM | Poster: Applications- Other topics | |
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer | 3/31/2008 10:40:25 AM | Poster: Applications- Oncology | |
Development AND External validation of a model for Glucuronidation in children below 3 years of age using morphine as a model drug; towards a novel dosing paradigm. | 3/26/2008 4:54:42 PM | Poster: Applications- Other topics | |
Bridging Cardiovascular Risk from Clinical Trials to Real Life Population | 3/28/2008 4:48:25 PM | Poster: Applications- CVS | |
K. Kuester(1,3), A. Kovar(2), C. Lüpfert(2), B. Brockhaus(2), C. Kloft(1,3) | Matuzumab – Evaluation of the Population Pharmacokinetic Model and Analyses of the Covariate Impact on the Pharmacokinetic Profile | 2/29/2008 3:40:19 PM | Poster: Applications- Oncology |
Exposure-Response Modeling of the ACR20 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. | 3/28/2008 4:54:29 PM | Poster: Applications- Biologicals/vaccines | |
Brigitte Lacroix(1), Philipp von Rosenstiel(2), Maria Laura Sargentini-Maier(1) | Population Pharmacokinetics of Brivaracetam in Patients with Partial Epilepsy | 3/18/2008 10:56:29 AM | Poster: Applications- CNS |
Exposure-response analysis of certolizumab pegol in Crohn’s disease population | 3/28/2008 4:24:55 PM | Poster: Applications- Biologicals/vaccines | |
Model-Based Analysis of a Longitudinal Binary Response as the Primary Analysis for a Phase II Study in Migraine Prophylaxis. | 3/20/2008 4:42:15 PM | Poster: Applications- CNS | |
C. Laveille (1), M. Lavielle (2,3), K. Chatel (4), P. Jacqmin (1) | Evaluation of the PK and PK-PD libraries of MONOLIX: A comparison with NONMEM | 3/31/2008 11:45:29 AM | Oral Presentation: Stuart Beal Methodology Session |
Analysing population PK/PD data with MONOLIX 2.4 | 5/28/2008 3:13:08 PM | Software demonstration | |
A Nonparametric Analogue to POSTHOC Estimates for Exploratory Data Analysis | 3/30/2008 2:51:23 PM | Poster: Methodology- Model evaluation | |
Stochastic pharmacokinetic models: selection of sampling times | 3/4/2008 3:42:19 PM | Oral Presentation: Methodology | |
Micha Levi (1), Nicolas Frey (2) , Susan Grange (2), Thasia Woodworth (3) | Relationship Between Serum Concentration of the Interleukin-6 Receptor Inhibitor, Tocilizumab (TCZ), and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis | 3/28/2008 10:05:22 PM | Poster: Applications- Biologicals/vaccines |
O. Lillin-de Vries, T. Kerbusch, P-J. de Kam, N. Ivgy-May, R. Bursi | A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers. | 3/20/2008 11:14:50 AM | Poster: Applications- CNS |
Andreas Lindauer (1), Christiane Eickhoff (2), Charlotte Kloft (2,3), Ulrich Jaehde (1) | Population Pharmacokinetics of High-dose Carboplatin | 3/28/2008 9:48:51 AM | Poster: Applications- Oncology |
Randomised dose controlled trials or concentration controlled trials when learning about drugs with narrow therapeutic index? | 3/28/2008 6:13:40 PM | Poster: Methodology- Design | |
Impact of study design for characterising PKPD covariance and nonlinearity in exposure-dichotomous response relationships | 3/28/2008 6:06:24 PM | Poster: Methodology- Design | |
Population Pharmacokinetics of Risperidone in Patients with Acute Schizophrenia | 3/31/2008 2:33:23 PM | Poster: Applications- CNS | |
Leveraging complicated PK/PD models for the development of a Bayesian adaptive Dose-ranging design. | 3/27/2008 5:09:12 PM | Poster: Methodology- Design | |
B. Boulanger (1), A. Jullion (1), J. Jaeger (2), M. Lovern (1) and C. Otoul (1) | Development of a Bayesian Adaptive Sampling Time strategy for PK studies with constrained number of samples to ensure accurate estimates. | 3/28/2008 2:56:29 PM | Poster: Methodology- Design |
PBPK modeling of metoprolol and its metabolites | 3/31/2008 11:39:35 PM | Poster: Methodology- PBPK | |
GastroPlus | 5/6/2008 2:45:38 PM | Software demonstration | |
Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin | 3/27/2008 5:20:04 PM | Poster: Applications- CNS | |
Scaling propofol doses for the obese: is lean body weight the answer? | 3/27/2008 1:53:17 AM | Poster: Applications- CNS | |
The Use of Clinical Trial Simulation to investigate Bias in Crossover Studies with a Short Washout Period and no Placebo Arm: Application to Neuropathic Pain | 3/31/2008 11:14:13 PM | Poster: Methodology- Design | |
Simulation and evaluation of bivariate Beta distribution for interval response variables | 2/14/2008 4:48:13 PM | Poster: Methodology- Algorithms | |
Kaori Ito*, Matt Hutmacher#, Jing Liu, Ruolun Qiu, Bill Frame, Raymond Miller | Exposure-Response Analysis of Longitudinal Adverse Event Data. | 3/26/2008 3:50:36 PM | Poster: Applications- CNS |
G. Morrish(1), C.Kirkpatrick(1), N. Byrne(2), H. Kinoshita(3) & B. Green(1) | Using Body Composition Metrics to Predict Exposure Between Japanese and Caucasian Populations | 3/31/2008 8:25:03 AM | Poster: Applications- Other topics |
Simultaneous Therapeutic Drug Monitoring Of Amikacin And Beta-Lactams In Intensive Care Unit Patients With Severe Sepsis Or Septic Shock Without Beta-Lactam Serum Concentration Monitoring | 3/15/2008 11:37:51 PM | Poster: Applications- Anti-infectives | |
Limited sampling formulas and bayesian estimation for mycophenolic acid 12 hours Area Under the concentration-time Curve prediction in Stable renal transplant recipients co-medicated with cyclosporine or sirolimus | 3/15/2008 11:24:45 PM | Poster: Applications- Other topics | |
Pharmacokinetic and Pharmacodynamic Model for Drug Induced Transient Transaminitis | 3/27/2008 1:20:38 PM | Poster: Methodology- Other topics | |
H Kimko, B Murthy, RS Strauss, S Xu, P Bagchi, P Nandy, K Bush, GJ Noel | Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with Complicate Skin and Skin Structure Infection | 4/14/2008 3:47:11 PM | Poster: Applications- Anti-infectives |
Navarro-Fontestad MC1, Fernández-Teruel C2, González-Álvarez I1, Bermejo M1, Casabo VG1. | Estimating the complete AUC and its standard error in sparse sampling designs. | 3/28/2008 2:24:50 PM | Poster: Methodology- Other topics |
Population Kinetics and Dynamics of Lopinavir in HIV-Infected Children | 3/30/2008 9:24:44 AM | Poster: Applications- Anti-infectives | |
Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Modelling and Simulation Based on Data from a Prospective Study | 3/28/2008 4:27:07 PM | Poster: Applications- Anti-infectives | |
Modelling and Simulation of Ketoconazole inhibition when co-administration time is not sufficient: role of CYP3A function recovery | 3/31/2008 5:46:29 PM | Poster: Methodology- Model evaluation | |
A sparse sample PK & PKPD approach to estimate the time course of antipsychotic-induced D2 occupancy | 3/31/2008 6:09:01 PM | Poster: Applications- CNS | |
Stefanie Hennig1, Joakim Nyberg1, Samuel Fanta1,2, Andrew Hooker1, Mats O. Karlsson1 | Application of the optimal design approach to improve therapeutic drug monitoring for cyclosporine | 5/20/2008 5:39:26 PM | Oral Presentation: Methodology |
Stefanie Hennig1, Sebastian Ueckert1,2, Joakim Nyberg1, Andrew Hooker1, Mats O. Karlsson1 | Application of Optimal Design for Disease Progression Studies | 5/20/2008 5:40:17 PM | Poster: Methodology- Design |
Dose and sample time optimization of drug candidate screening experiments | 3/28/2008 5:39:51 PM | Poster: Methodology- Design | |
An Effective approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments | 3/31/2008 1:55:21 PM | Poster: Methodology- Design | |
Model-based dose adaptation of capecitabine for prevention of severe hand-and-foot syndrome: in silico comparison with the standard method | 3/15/2008 4:23:15 PM | Oral Presentation: Applications | |
Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM VI | 3/31/2008 1:53:55 PM | Poster: Methodology- Other topics | |
E. Pigeolet (1), F. Luedicke (2), S. Balser (2), G. Pinault (1) and P. Lowe (1) | Granulocyte Colony Stimulating Factor Pharmacokinetics After Single and Repeated Administration of Several Doses. | 3/26/2008 9:33:30 PM | Poster: Applications- Biologicals/vaccines |
Elodie Plan (1), Alan Maloney (2), Iñaki F. Trocóniz (3), Mats O. Karlsson (1) | Maximum Likelihood Estimation Methods: Performances in Count Response Models Population Parameters | 3/31/2008 3:10:08 PM | Oral Presentation: Stuart Beal Methodology Session |
Evaluation of direct population PKPD models for truncated concentration-response curves | 3/31/2008 11:49:49 AM | Poster: Methodology- Design | |
Bizzotto R (1), Nucci G (2), Petrone M (2), Poggesi I (2), Cobelli C (1), Gomeni R (2) | Evaluation of a basic PBPK model in preclinical species for which tissue compositions are unknown | 3/31/2008 4:51:58 PM | Poster: Methodology- PBPK |
Teun Post(1), Rik de Greef(1), Thomas Kerbusch(1), Lambertus Peletier(2), Meindert Danhof(3) | Disease System for osteoporosis: relating bone mineral density with measures of bone formation and resorption based on bone biology | 3/31/2008 12:17:38 PM | Poster: Applications- Endocrine |
Optimizing Calcineurin Inhibitor Exposure In De Novo Kidney Transplant Recipients | 3/19/2008 6:10:52 PM | Poster: Applications- Other topics | |
Mango Solutions | 5/14/2008 8:22:04 PM | Software demonstration | |
Angelica L. Quartino (1), Lena E. Friberg (1), Sharon D. Baker (2) and Mats O. Karlsson (1) | Comparison Between using Continuous and Categorical Toxicity Data for Estimation with a Model for Continuous Data | 3/31/2008 11:16:20 PM | Poster: Methodology- Other topics |
S. Dittberner (1), V. Duval (2), A. Staab (2), U. Graefe-Mody (2), U. Jaehde (1) | BI 1356 (proposed trade name ONDERO) pharmacokinetics and DPP-4 inhibition: Development of a target mediated PKPD model in type 2 diabetic patients | 3/29/2008 9:31:49 AM | Poster: Applications- Endocrine |
S. Dittberner (1), V. Duval (2), A. Staab (2), U. Jaehde (1) | Target mediated drug disposition model for the DPP-4 inhibitor BI1356 (proposed trade name ONDERO): Is the structure identifiable? | 3/29/2008 9:38:36 AM | Poster: Applications- Endocrine |
Design optimisation in nonlinear mixed effects models using cost functions: application to a joint model of infliximab and methotrexate pharmacokinetics | 3/30/2008 4:57:22 PM | Oral Presentation: Methodology | |
B. Ribba, K. Chatel, M. Tod, P. Girard, G. Freyer, B. Tranchand | Monolix benefits from external modules to manage complex ODE: Illustration with a population analysis of Irinotecan and its metabolites. | 3/31/2008 2:30:57 PM | Poster: Methodology- Algorithms |
J. Ribbing (1), B. Hamrén (1,2), M.K. Svensson (2,3) and M.O. Karlsson (1) | Modelling the Dynamics of Glucose, Insulin, Insulin Sensitivity and Beta-Cells in Subjects with Insulin Resistance and Patients with Type 2 Diabetes | 3/14/2008 11:33:10 AM | Oral Presentation: Lewis Sheiner Student Session |
Extended Link Model to Describe the Impact of Chronic Antiepileptic Therapy on the Effects of Neuromuscular Blocking Agents. | 3/31/2008 8:38:02 PM | Poster: Applications- CNS | |
Population Pharmacokinetics of Efavirenz and MDR-1, CY2B6, and CYP3A5 Polymorphisms | 3/28/2008 4:35:01 PM | Poster: Applications- Anti-infectives | |
A. Russu (1), G. De Nicolao (1), I. Poggesi (2), M. Neve (2), L. Iavarone (2), R. Gomeni (2) | Dose escalation studies: a comparison between NONMEM and a novel Bayesian tool | 3/30/2008 3:10:19 AM | Poster: Methodology- Design |
David H. Salinger (1), Jeannine S. McCune (2), David K. Blough (2), Paolo Vicini (1) | Mean Squared Error as Criterion for Sampling Schedule Optimization for Individual Dose Targeting in IV Busulfan | 4/1/2008 12:35:31 AM | Poster: Methodology- Design |
A novel bootstrap method for obtaining uncertainty measurement around the nonparametric distribution | 3/31/2008 7:12:14 PM | Poster: Methodology- Other topics | |
External validation of a model based on cystatin C to predict carboplatin clearance | 5/20/2008 1:02:43 PM | Poster: Applications- Oncology | |
Nabil Semmar, Saik Urien, Bernard Bruguerolle and Nicolas Simon | Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves | 3/1/2008 1:34:32 PM | Poster: Methodology- Other topics |
C.M.T. Sherwin (1, 2), N.J. Medlicott (2), R. Broadbent (1), D.M. Reith (1). | Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates. | 2/19/2008 11:33:07 PM | Poster: Applications- Anti-infectives |
Hanna E Silber, Joakim Nyberg, Andrew Hooker, Mats O Karlsson | Improvement of the intravenous glucose tolerance test using optimal experimental design. | 3/31/2008 11:19:22 AM | Poster: Methodology- Design |
M. Simeoni(1), C. Chen(1), P. Dua(2), R.E. Oliver-Willwong (1), D. J. Austin(1) | Modelling beta amyloid system: sensitivity analysis at steady state and in dynamic conditions. | 3/31/2008 8:47:14 PM | Poster: Applications- CNS |
Population Pharmacokinetics of Atazanavir in HIV-infected Patients | 1/31/2008 11:14:07 AM | Poster: Applications- Anti-infectives | |
J. Smeets(1), B. Ploeger(1), A. Strougo(1), L. Liefaard(1), T. Kerbusch(2) | A Mechanism-based Pharmacokinetic Model Describing the Interaction Between Sugammadex and Rocuronium in Patients with Normal and Impaired Renal Function | 3/20/2008 4:47:28 PM | Poster: Applications- Other topics |
Eric Snoeck (1), Marc Lavielle (2,3), Pascal Chanu (4), Karin Jorga (4) and Nicolas Frey (4) | The challenge of modelling hepatitis C virus dynamics after long term treatment: Application of MONOLIX | 3/31/2008 8:51:08 AM | Oral Presentation: Methodology |
A semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the new PLK-1 inhibitor BI 2536 and its application in clinical development | 3/24/2008 10:58:18 AM | Poster: Applications- Oncology | |
Predicting Paediatric Tobramycin Pharmacokinetics with Five Different Methods | 3/31/2008 10:21:31 PM | Oral Presentation: Applications | |
E. Snoeck (1), R. Schoemaker (1), A. Stockis (2), C. Otoul (2), M.L. Sargentini-Maier (2) | Levetiracetam exposure-response analysis in children with partial onset seizures | 3/31/2008 10:47:58 PM | Poster: Applications- CNS |
Population pharmacokinetics of lumefantrine in pregnant women treated with co-artemether for uncomplicated falciparum malaria | 3/31/2008 8:35:19 PM | Poster: Applications- Anti-infectives | |
D Ternant, A Aubourg, C Magdelaine-Beuzelin, D Degenne, H Watier, L Picon and G Paintaud. | Development of anti-infliximab antibodies increases infliximab clearance in inflammatory bowel diseases | 3/31/2008 2:20:08 PM | Poster: Applications- Biologicals/vaccines |
Reduced Folate Carrier Single Nucleotide Polymorphism Associated with Methotrexate Clearance in Breast Cancer Patients | 3/28/2008 11:17:20 AM | Poster: Applications- Oncology | |
RfN, R for Nonmem: A graphical interface for Nonmem outputs | 5/6/2008 2:49:32 PM | Software demonstration | |
Population pharmacokinetic models for lamivudine and nevirapine to assess drug concentrations obtained during therapeutic drug monitoring | 3/31/2008 5:57:03 PM | Poster: Applications- Anti-infectives | |
Tamara van Steeg, Ashley Strougo, Bart Ploeger and Piet Hein van der Graaf | Assessment of the use of complex baseline models in preclinical safety screening: Application of the van der Pol oscillator model to describe heart rate effects in rats | 3/31/2008 8:58:33 AM | Poster: Applications- Other topics |
Time Course of Disease Status as a Predictor of Clinical Outcome in Parkinson’s Disease | 3/14/2008 11:24:03 AM | Oral Presentation: Lewis Sheiner Student Session | |
K. Vucicevic(1), B. Miljkovic(1), M. Pokrajac (1), I. Grabnar(2) | Estimation of Relative Bioavailability of Controlled-Release Carbamazepine Tablets Based on Routine TDM Data | 3/31/2008 4:12:52 PM | Poster: Applications- CNS |
Johan E Wallin (1), Lena E Friberg (1), Christine E Staatz (2) | Population pharmacokinetics of tacrolimus in paediatric heamatopeitic stem cell transplantation | 3/29/2008 5:47:04 PM | Poster: Applications- Other topics |
Hands-On Demonstrations of the Physiology-Based Pharmacokinetic Software, PK-Sim® | 5/7/2008 4:56:22 PM | Software demonstration | |
Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody | 3/26/2008 10:37:07 AM | Poster: Applications- Biologicals/vaccines | |
Using M&S to Shorten the Repeating Cycle of the Early Drug Development Process: A Case Study | 3/21/2008 1:55:52 PM | Poster: Applications- Other topics | |
Dose Selection for Combination Drug Products | 3/20/2008 6:41:46 PM | Poster: Applications- Other topics | |
Relationship between the Dose of Recombinant Human Growth Hormone (rhGH) and Insulin Growth Factor-1 (IGF-1) in Adult Patients with Growth Hormone Deficiency (AGHD) | 3/27/2008 12:09:49 PM | Poster: Applications- Endocrine | |
Model-Based Drug Development (MBDD) of Pegylated Growth Hormone (PEG-hGH) in the Treatment of Adult Growth Hormone Deficient (AGHD) | 3/27/2008 12:25:06 PM | Poster: Applications- Endocrine | |
Exposure-Response Analysis of Adverse Events in Clinical Trials Using Zero-Inflated Poisson Modeling With NONMEM®. | 3/21/2008 9:16:32 PM | Poster: Methodology- Other topics | |
Evaluation of Population PK/PD for Osteoporosis during a Vitamin D3 (1,25(OH)2D3) Derivative Therapy | 1/28/2008 1:35:39 AM | Poster: Applications- Other topics | |
Adaptive Optimal Design in PET Occupancy Studies | 3/31/2008 5:38:08 PM | Poster: Methodology- Design | |
Bizzotto R (1), Zamuner S (2), Nucci G (2), Cobelli C (1), Gomeni R (2) | Mixed Effects Markov Models for Modelling Sleep in Insomniac Patients Treated with Placebo in a 28 Days Trial: Emphasis on the Break Points Selection | 3/31/2008 5:44:11 PM | Poster: Applications- CNS |
Anthe Zandvliet, Anton de Haan, Pieta IJzerman-Boon, Rik de Greef, Thomas Kerbusch. | PK-PD model of multiple follicular development with corifollitropin alfa during controlled ovarian stimulation: application of Markovian elements. | 3/31/2008 10:12:00 AM | Oral Presentation: Stuck in Modelling |
Zhao W (1), Baudouin V (2), Zhang D (1) and Jacqz-Aigrain E (1) | Population Pharmacokinetics of Ganciclovir Following Oral Administration of its Prodrug Valganciclovir in Pediatric Renal Transplant Patients | 2/27/2008 1:15:51 PM | Poster: Applications- Anti-infectives |
